Prothena (PRTA)
(Delayed Data from NSDQ)
$20.87 USD
+0.31 (1.51%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $20.87 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Brokerage Reports
0 items in cart
Prothena Corporation plc [PRTA]
Reports for Purchase
Showing records 321 - 329 ( 329 total )
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY.
Provider: Roth Capital Partners, Inc.
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Initiating Coverage with OUTPERFORM Rating, $18 Price Target.
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Initiating Coverage with OUTPERFORM Rating, $18 Price Target
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
We launch coverage with a Buy and a $16 target.
Provider: Roth Capital Partners, Inc.
Analyst: HAZLETT R